Every material Form 8-K Krystal Biotech filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Krystal Biotech director Kirti Ganorkar gave notice on December 22, 2025 that he will resign from the Board. He will remain a director through December 31, 2025, and the company said the move was due to time constraints from his recent promotion at Sun Pharma, not a disagreement with the Board or management.
Kirti Ganorkar gave notice of resignation from the Board on December 22, 2025
He will continue as a director through December 31, 2025
Resignation attributed to time constraints from a recent promotion to Managing Director at Sun Pharma, not a disagreement with the company
He had served on the Board since the company's September 2017 initial public offering
Krystal Biotech reported third-quarter 2025 product revenue of $97.8 million, up from $83.8 million a year earlier, and net income of $79.4 million, or $2.66 per diluted share, versus $27.2 million, or $0.91, in the prior-year quarter. Net income was helped by a $31.4 million income tax benefit, and the company had $864.2 million in cash and investments at quarter end.
Q3 2025 product revenue, net was $97.8 million versus $83.8 million in Q3 2024.
Q3 2025 net income was $79.4 million ($2.66 diluted per share), including a $31.4 million income tax benefit.
Income from operations was $41.4 million versus $22.5 million a year earlier.
FY 2025 non-GAAP combined R&D and SG&A expense guidance is $145.0 million to $155.0 million.
Krystal Biotech reported second-quarter 2025 product revenue of $96.0 million, up from $70.3 million a year earlier, and net income of $38.3 million, or $1.29 per diluted share, compared with $15.6 million, or $0.53 per diluted share, in the prior-year quarter. The company also reported $820.8 million in cash and investments and issued FY 2025 non-GAAP R&D and SG&A expense guidance of $150.0 million to $175.0 million.
Q2 2025 product revenue, net: $96.0 million vs. $70.3 million in Q2 2024
Q2 2025 net income: $38.3 million ($1.29 per diluted share) vs. $15.6 million ($0.53) a year earlier
Cash, cash equivalents and investments: $820.8 million as of June 30, 2025
FY 2025 non-GAAP R&D and SG&A expense guidance: $150.0 million to $175.0 million
Krystal Biotech reported first-quarter 2025 results, with product revenue of $88.2 million, up from $45.3 million a year earlier, and net income of $35.7 million, or $1.20 per diluted share, compared with $0.9 million in the prior-year quarter. The company also gave full-year 2025 non-GAAP R&D and SG&A expense guidance of $150.0 million to $175.0 million, and it reported $765.3 million in cash and investments.
Product revenue, net: $88.2 million in Q1 2025 versus $45.3 million in Q1 2024
Net income: $35.7 million ($1.24 basic, $1.20 diluted per share) versus $0.9 million ($0.03 per share) in Q1 2024
FY 2025 non-GAAP R&D and SG&A expense guidance: $150.0 million to $175.0 million, excluding stock-based compensation
Cash, cash equivalents, and investments: $765.3 million as of March 31, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Krystal Biotech filing is on SEC EDGAR ↗. 8-K briefs of other companies →